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Involvement of the agmatinergic system in the depressive-like
phenotype of the Crtc1 knockout mouse model of depression
EM Meylan1,2, L Breuillaud1,2,7, T Seredenina3,8, PJ Magistretti1,4,5, O Halfon2, R Luthi-Carter3,6 and J-R Cardinaux1,2
Recent studies implicate the arginine-decarboxylation product agmatine in mood regulation. Agmatine has antidepressant
properties in rodent models of depression, and agmatinase (Agmat), the agmatine-degrading enzyme, is upregulated in the brains
of mood disorder patients. We have previously shown that mice lacking CREB-regulated transcription coactivator 1 (CRTC1) associate
behavioral and molecular depressive-like endophenotypes, as well as blunted responses to classical antidepressants. Here, the
molecular basis of the behavioral phenotype of Crtc1−/− mice was further examined using microarray gene expression proﬁling that
revealed an upregulation of Agmat in the cortex of Crtc1−/− mice. Quantitative polymerase chain reaction and western blot analyses
conﬁrmed Agmat upregulation in the Crtc1−/− prefrontal cortex (PFC) and hippocampus, which were further demonstrated by
confocal immunoﬂuorescence microscopy to comprise an increased number of Agmat-expressing cells, notably parvalbumin- and
somatostatin-positive interneurons. Acute agmatine and ketamine treatments comparably improved the depressive-like behavior of
male and female Crtc1−/− mice in the forced swim test, suggesting that exogenous agmatine has a rapid antidepressant effect
through the compensation of agmatine deﬁcit because of upregulated Agmat. Agmatine rapidly increased brain-derived neurotrophic
factor (BDNF) levels only in the PFC of wild-type (WT) females, and decreased eukaryotic elongation factor 2 (eEF2) phosphorylation in
the PFC of male and female WT mice, indicating that agmatine might be a fast-acting antidepressant with N-methyl-D-aspartate
(NMDA) receptor antagonist properties. Collectively, these ﬁndings implicate Agmat in the depressive-like phenotype of Crtc1−/−mice,
reﬁne current understanding of the agmatinergic system in the brain and highlight its putative role in major depression.
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INTRODUCTION
Major depressive disorder (MDD) is a complex neuropsychiatric
disease comprising one of the leading causes of disability
worldwide, with an estimated lifetime prevalence of 16%.1
However, the etiological mechanisms underlying MDD are not
clearly established. Studies over the past decades have suggested
that altered neuroplasticity is a cardinal feature of MDD,2 leading
to the network hypothesis of depression. This latter proposes that
impaired neuroplasticity related to problems in activity-dependent
neuronal communication might alter information processing in
the affected neural networks, and ultimately cause MDD.3 In line
with this hypothesis, antidepressants have been shown to
promote synaptogenesis, neurogenesis and dendritic growth in
the hippocampus (HIP) of rodents.4,5 These neurotrophic effects
correlate with positive behavioral responses to antidepressants
and are thought to rely, at least partly, on the activation of cAMP-
response element-binding protein (CREB)-regulated genes, includ-
ing increased signaling of the brain-derived neurotrophic factor
(BDNF)-TrkB pathway.4 We and others have previously shown
that CREB-dependent Bdnf expression requires CREB-regulated
transcription coactivator 1 (CRTC1).6–8 CRTC1 has been shown to
act as a neuronal calcium- and cAMP-sensitive coincidence
detector and to promote CREB-dependent transcription.6,9 In
addition to its important role in Bdnf expression, CRTC1 has also
been shown to be critical for speciﬁc aspects of neuroplasticity, as
evidenced by its role in dendritic growth of developing cortical
neurons10,11 and its requirement for maintenance of long-term
potentiation in the HIP.6,8
To further understand the role and function of CRTC1, we
generated a Crtc1-deﬁcient mouse line.12 These mice present
behavioral and molecular features mirroring mood disorders, such
as increased behavioral despair, anhedonia, increased irritability/
aggressiveness, decreased sexual motivation, social withdrawal,
decreased dopamine and serotonin turnover in the prefrontal
cortex (PFC), as well as decreased HIP and PFC expression in several
neuroplasticity-related genes including Bdnf and its receptor TrkB.13
Furthermore, Crtc1−/− mice exhibit a blunted antidepressant
response to the selective serotonin reuptake inhibitor ﬂuoxetine
and to the tricyclic antidepressant desipramine in a behavioral
despair paradigm.13,14 Taken together, these ﬁndings suggest an
important role for CRTC1 in the etiology of MDD and a possible
involvement in treatment-resistant depression.
Substantial evidence supports the involvement of the arginine-
decarboxylation product agmatine in MDD. This metabolite is
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widely expressed in several mammalian organs, including the
brain. Agmatine synthesis competes with other arginine-
dependent pathways, such as the urea cycle and nitric oxide
(NO) synthesis.15 It is degraded by the enzyme agmatinase
(Agmat) into putrescine, a key precursor for polyamine
synthesis.15,16 Accumulating evidence suggests that polyamines
and their precursors have a role in the etiology and pathology of
mental disorders, notably in mood disorders and suicidal
behavior.17,18 Agmatine has also been proposed to function as a
neurotransmitter: it is stored in synaptic vesicles and released
upon depolarization, followed by selective reuptake or
degradation.19 In addition, agmatine has the ability to bind a wide
range of receptors, including nicotinic receptors, imidazoline I1 and
I2 receptors, α2-adrenergic receptors and serotoninergic 5HT-2A
and 5HT-3 receptors.20–23 Remarkably, agmatine also acts as a
glutamate N-methyl-D-aspartate receptor (NMDAR) antagonist.24
This property is particularly interesting in light of the recent and
growing interest in glutamate-based rapid-acting antidepressants,
whose prototype is the NMDAR antagonist ketamine.25–29
Importantly, humans affected by depression show altered blood
levels of agmatine, and post-mortem studies have shown increased
Agmat levels in brain tissues from depressed individuals.30,31 In
rodents, cortical and hippocampal agmatine levels are decreased by
restraint stress, and agmatine demonstrates neuroprotection against
acute and chronic stress effects.32–35 Furthermore, acute agmatine
treatment has rapid antidepressant activities in depression-related
paradigms such as the forced swim test (FST) and tail suspension
test.36 These effects have been attributed to agmatine actions on
monoaminergic and opioid systems, imidazoline and α2-adrenergic
receptors, and NMDAR blockade.36–39 Moreover, agmatine has the
ability to modulate pro- and anti-oxidative balance in the HIP, which
might also underlie its behavioral effects.34 Finally, a recent study
has shown that in parallel to its antidepressant activity, agmatine
increases HIP CREB phosphorylation and BDNF levels, and induces
cell survival pathways.40 Altogether, these data suggest that
agmatine stimulates several endogenous mood-regulating mechan-
isms known to be altered in MDD, leading to the conclusion that
dysregulation of the agmatinergic system could play a role in the
etiopathogenesis of MDD and agmatine supplementation might
have a positive outcome on the disease.
In this study, we investigated the molecular basis for the
depressive-like phenotype of Crtc1−/− mice, which led us by
differential expression analysis to discover a cortical upregulation
of Agmat expression. Immunohistochemical studies revealed that
mutant mice have an increased number of Agmat-expressing cells
in the PFC and HIP, particularly parvalbumin (PV)- and somatos-
tatin (Sst)-positive interneurons. Based on this result, we
hypothesized that increased Agmat levels would result in reduced
agmatine bioavailability in the brains of Crtc1−/− mice, and that
supplementation with exogenous agmatine would improve their
depressive-like behavior. Indeed, we found that acute agmatine
administration had a rapid antidepressant effect both in wild-type
(WT) and Crtc1−/−mice, the latter requiring a higher dose than WT,
in accordance with their increased brain Agmat levels. Finally, we
also investigated the molecular mechanisms underlying the rapid
antidepressant effects of exogenous agmatine in WT and Crtc1−/−
mice. We found that agmatine induced BDNF translation in the
PFC of WT mice, paralleled by dephosphorylation of eukaryotic




Crtc1−/− mice and WT littermates were generated and genotyped as
previously described.12 Mice were housed under a 12-h light–dark cycle
with ad libitum access to water and standard rodent chow diet. All animal
experiments were conducted in accordance with the Swiss Federal
Veterinary Ofﬁce’s guidelines and were approved by the Cantonal
Veterinary Service. All behavioral tests were carried out in the dark phase
of the reverse light cycle according to the standard procedures. Male and
female mice were weaned at 21 days and housed in same-sex sibling
groups until being isolated at 5 weeks of age in order to avoid wounding
of cage mates by aggressive Crtc1−/− male mice.13 At the age of 8 weeks,
animals were randomly assigned into treatment groups and either killed
for molecular experiments or used for behavioral assessments.
Brain microdissection
Male and female mice were killed by cervical dislocation, and the brain was
rapidly placed in a stainless steel adult mouse brain slicer matrix with 1-
mm coronal section slice intervals. A ﬁrst cut included the PFC from which
the olfactory bulbs and associated structures were removed. Total
hippocampi were unrolled from the cortex. All the structures were
sequentially quick-frozen in dry ice for mRNA and protein extraction and
stored at − 80 °C until further processing.
Gene expression analysis
Total RNA was extracted and puriﬁed from the PFC and HIP using the
RNAeasy Plus Minikit (Qiagen, Hombrechtikon, Switzerland) according to
the manufacturers’ instructions. RNA concentrations were measured by
Ultraviolet spectophotometry with a NanoDrop Lite (Thermo Scientiﬁc,
Wilmington, DE, USA). Complementary DNA was prepared in a 50-μl
reaction by reverse transcription, using 200 ng of RNA with Taqman
Reagents and random hexamers (Applied Biosystems, Foster City, CA, USA).
Complementary DNA (0.8 μl) was ampliﬁed on a 96-well plate using the
SYBR Green PCR Master Mix (Applied Biosystem). Ampliﬁcation was
performed with an ABIPRISM 7500 real-time PCR system (Applied
Biosystem). The program was 2 min at 50 °C, 10 min at 95 °C, followed
by 45 cycles of 15 s at 95 °C and 1 min at 60 °C. Relative gene expression
was quantiﬁed using the comparative ΔΔ Ct method and normalized with
β-actin transcript levels.
The following primers were used at a concentration of 250 nM: β-actin
forward 5′-GCTTCTTTGCAGCTCCTTCGT-3′, β-actin reverse 5′-ATATCGTCAT
CCATGGCGAAC-3′, Agmat forward 5′-TGGACAGCAAGCGAGTGGTACA-3′,
Agmat reverse 5′-GGACCAGTGACTTCATCCAACAG-3′.
Affymetrix gene expression arrays
Gene expression levels were evaluated using DNA microarrays (GeneChip
Mouse Genome 430 version 2.0, Affymetrix, Santa Clara, CA, USA) and RNA
from the cerebral cortices of female mice (n=5 for WT and n= 5 for
Crtc1−/−). Biotinylated cRNAs were prepared from 300 ng total RNA using
the GeneChip 3′ IVT Express Kit (Affymetrix) following the manufacturer’s
instructions. cRNA (15 μg) was hybridized to GeneChip arrays and
processed, stained and scanned according to the manufacturer’s
recommendations. The quality of input RNAs and cRNAs was veriﬁed with
the Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA) before
use. Microarray quality control was performed using the software package
provided on RACE.41 Chips with a median-normalized unscaled s.e. greater
than 1.05 were excluded. Affymetrix annotations (version 3.0) were used
for probeset-to-gene assignments. Mod t-statistics and false discovery rate
corrections for multiple testing with a signiﬁcance threshold of Po0.05
were used as criteria for differential expression, as described in Hochberg
and Benjamini.42 Microarray data have been deposited in NCBI's Gene
Expression Omnibus (GEO) and are accessible through GEO Series
accession number GSE80633 (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc =GSE80633).
Western blot
PFC and HIP samples were manually homogenized with a microtube pestle
in RIPA buffer (50 mM HEPES (pH 7.6), 150 mM NaCl, 1 mM EDTA (pH 7.5),
2.5 mM EGTA (pH 8.0), 10% glycerol, 1% NP-40, 1% deoxycholate, 0.1% SDS,
with a protease inhibitor cocktail (Sigma, St Louis, MO, USA) and a
phosphatase inhibitor cocktail (PhosSTOP, Roche, Rotkreuz, Switzerland)
and extracted for 20 min at 4 °C. Protein quantiﬁcation was performed with
the Pierce BCA Protein Assay Kit (Thermo Scientiﬁc). Samples with low-
protein extract (o2 mg ml− 1) were excluded. Fifty μg of tissue homo-
genates were diluted 1:1 with sample buffer (50 mM Tris-HCl (pH 6.8),
100 mM dithiothreitol, 2% SDS, 9% glycerol, 1% bromophenol blue),
separated on a 12% SDS-polyacrylamide gel and proteins were transferred
to polyvinylidene diﬂuoride membranes with a semi-dry blotting system
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(Bio-Rad, Hercules, CA, USA). Blots were blocked for 1 h at room
temperature (RT) in TBST (10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1%
Tween-20), supplemented with 5% skim milk powder. Blots were
subsequently incubated with a primary antibody in TBST plus 5% bovine
serum albumin overnight at 4 °C. Finally, polyvinylidene diﬂuoride
membranes were incubated for 1 h at RT with horseradish peroxidase
(HRP)-conjugated secondary antibodies in TBST plus 5% skim milk powder,
and were developed using a Pierce ECL Western Chemiluminescence
Detection Kit (Thermo Scientiﬁc). The following antibodies and dilutions
were used: rabbit α-Agmat 1:400 (sc-98802, Santa Cruz Biotechnology,
Dallas, TX, USA), rabbit α-BDNF 1:500 (sc-546, Santa Cruz Biotechnology),
rabbit α-phospho-eEF2 1:1000 (#2331, Cell Signaling, Danvers, MA, USA),
rabbit α-eEF2 1:1000 (#2332, Cell Signaling), mouse α-β-actin 1:10 000 (Ab-
6276, Abcam, Cambridge, UK), donkey HRP-α-rabbit 1:2000 (#NA934, GE
Healthcare, Little Chalfont, UK) and sheep HRP-α-mouse 1:2000 (#NA931,
GE Healthcare). Quantiﬁcation of band intensity was performed with the
Image J software (National Institute of Health, Bethesda, MD, USA). Agmat
and BDNF band intensities were normalized with β-actin signals; phospho-
eEF2 band intensities were normalized with total eEF2 signals.
Immunoﬂuorescence
Eight-week-old male mice were deeply anesthetized using sodium
pentobarbital and intracardially perfused with saline followed by 4%
buffered paraformaldehyde. Brains were dissected out, postﬁxed for 1 h in
4% paraformaldehyde and cryoprotected in 30% sucrose. Brain sections of
35 μm were cut with a freezing microtome (Microm, Thermo Fisher
Scientiﬁc, Waltham, MA, USA) and stored at − 20 °C in a cryoprotectant
solution. Blocking (1 h, RT) as well as primary (overnight, 4 °C) and
secondary antibody incubation (1 h, RT) were performed in phosphate-
buffered saline+0.3% Triton X-100+2% normal horse serum+0.2% bovine
serum albumin. Slices were washed three times in phosphate-buffered
saline+0.3% Triton X-100 after each incubation. The following antibodies
and dilutions were used: rabbit α-Agmat 1:100 (sc-98802, Santa Cruz
Biotechnology), mouse α-Parvalbumin 1:2500 (PV235, Swant, Marly,
Switzerland), mouse α-Calretinin 1:2500 (CR7697, Swant), goat α-Somatos-
tatin 1:500 (sc-7819, Santa Cruz Biotechnology), Cy3-conjugated donkey α-
rabbit 1:500 (#711-165-152, Jackson Immunoresearch, West Grove, PA,
USA), Alexa Fluor 488-conjugated goat α-mouse 1:500 (A-21121, Molecular
Probes, Eugene, OR, USA) and Alexa Fluor 488-conjugated donkey α-goat
1:500 (A11055, Invitrogen, Carlsbad, CA, USA). After the secondary
antibody incubation, slices were washed, stained with 4,6-diamidino-2-
phenylindole 1:30 000 (Invitrogen), mounted on glass slides with the
antifade Vectashield medium (Vector Laboratories, Burlingame, CA, USA)
and analyzed with a Zeiss LSM 710 Quasar Confocal Microscope (Carl Zeiss,
Oberkochen, Germany). Image processing and cell counting were carried
out with the Image J Software (National Institute of Health).
Agmatine and ketamine treatment
Agmatine sulphate salt and ketamine (Ketanarkon) were, respectively,
purchased from Sigma and Streuli Pharma (Uznach, Switzerland) and
dissolved in saline solution. Male and female mice were intraperitoneally
injected with 10 ml kg− 1 of agmatine (10 or 50 mg kg− 1) or ketamine
(3 mg kg− 1). Controls were injected with saline. Injections were performed
30 min before the FST for two consecutive days.
FST
A 2-day test was performed (days 1 and 2). Mice were put during 5 min in a
5-l glass beaker (26 cm tall, ø18 cm) ﬁlled to a depth of 22 cm with tap
water (25 ± 1 °C). Sessions were videotaped from above and manually
analyzed non-blindly by the experimenter with the Ethovision 3.1 Software
(Noldus Information Technology, Wageningen, The Netherlands) for
immobility and climbing time. Mice were judged immobile when no
detectable movement was observed, except for minor movements to keep
their head above the water. The experiment was conducted in a room with
a light intensity of ~ 35 lux. Immediately after the test on day 2, mice were
killed for BDNF and phospho-eEF2 measurements.
Statistical analyses
The number of animals tested in each group is speciﬁed in the ﬁgure
legends. Owing to the small number of WT and Crtc1−/−mice per litter and
a limited breeding cage space, all experiments were performed
sequentially with several batches of mice, and their data were combined.
Sample sizes were determined based on power analysis and common
practice in behavioral experiments (~10 animals per group). Statistical
analyses (other than those employed for microarray analyses (see above))
were performed using the Statistica 8.0 Software (StatSoft, Tulsa, OK, USA).
All data are presented as mean± s.e.m. Po0.05 were considered
statistically signiﬁcant. A Shapiro–Wilk test and a Levene test were ﬁrst
performed to assess data normality and variance homogeneity. All results
were found to follow normal distribution and to display similar variance.
For immunoﬂuorescence, quantitative PCR and western blot data, a two-
tailed Student's t-test was performed when only two groups were
compared (WT versus Crtc1−/− mice). For behavioral data, BDNF and
phospho-eEF2 data, a two-way analysis of variance (ANOVA; with genotype
and treatment as independent variables) was performed, followed by a
Fisher's Least Signiﬁcant Difference (LSD) post hoc test.
RESULTS
Male and female Crtc1−/− mice exhibit increased levels of Agmat
mRNA and protein in the PFC and HIP
To identify gene expression changes associated with Crtc1
deﬁciency, we performed genome-wide transcriptomic proﬁling
analyses of cortical samples from Crtc1−/− and WT female mice
using oligonucleotide microarrays (Table 1). Among the down-
regulated genes were CREB target genes that we previously
showed to have a decreased expression in the PFC and HIP of
Crtc1−/− male mice.13 Interestingly, a few genes were upregulated
in Crtc1−/− mice, and amidst them Agmat, whose expression was
increased by 1.67-fold. To follow up and conﬁrm this ﬁnding, we
measured Agmat messenger RNA (mRNA) and protein levels in
male and female Crtc1−/− mice (Figure 1). We focused our
investigations on the PFC and HIP, as these two regions are widely
implicated in mood disorders and are known to have high levels
of agmatine.43 Quantitative PCR analyses of Agmat mRNA levels
found a signiﬁcant (t=− 3.31, degree of freedom (df) = 9, P= 0.013)
1.5-fold increase of Agmat mRNA in the HIP and a threefold
increase (t=− 6.72, df = 8, Po0.001) in the PFC of male Crtc1−/−
Table 1. Selection of genes differentially expressed in the cortex of Crtc1−/− mice
Symbol Gene GenBank Fold change FDR P
Cartpt CART prepropeptide NM_013732 0.42 0.0086
Nr4a1 Nuclear receptor subfamily 4, group A, 1 NM_010444 0.50 0.0181
Nr4a3 Nuclear receptor subfamily 4, group A, 3 NM_015743 0.52 0.0103
Crem cAMP responsive element modulator NM_001110859 0.59 0.0028
Bdnf Brain-derived neurotrophic factor NM_007540 0.61 0.0131
Nr4a2 Nuclear receptor subfamily 4, group A, 2 NM_013613 0.70 0.0476
Ntrk2 Neurotrophic tyrosine kinase receptor, 2 (TrkB) NM_008745 0.81 0.0108
Agmat Agmatine ureohydrolase (agmatinase) NM_001081408 1.67 0.0099
Abbreviation: FDR P, false discovery rate corrected P-value.
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mice (Figure 1a). In female Crtc1− /− mice, a signiﬁcant (t=− 2.65,
df = 9, P= 0.029) threefold increase in Agmat mRNA was observed
in the HIP and a 2.5-fold increase (t= 5.45, df = 9, Po0.001) in the
PFC (Figure 1b). Western blot analysis of extracts from these same
structures showed an Agmat protein band at the expected size of
~ 35 kDa (Figures 1c and e), which was subsequently quantiﬁed
(normalized to β-actin signal). Crtc1−/− male mice had increased
levels of Agmat protein in the HIP (t=− 2.72, df = 6, P= 0.036),
whereas a nonsigniﬁcant trend (t=− 1.51, df = 9, P= 0.152) of
increased Agmat was observed in the PFC (Figure 1d). In female
Crtc1−/− mice, a similar increase was found in the HIP (t=− 2.58,
df = 9, P= 0.027), whereas no change in Agmat protein content
could be seen in the PFC (t=− 0.61, df = 9, P= 0.553; Figure 1f).
Taken together, these results conﬁrm an upregulation of Agmat
gene expression in the HIP and PFC of Crtc1−/− mice, indepen-
dently of gender. Although Agmat protein levels only partially
correlated with the gene expression data (which might reﬂect
translational regulation or a complex subcellular protein localiza-
tion), these results strongly suggest that Crtc1−/− mice have an
altered agmatinergic system.
Crtc1−/− mice have an increased number of Agmat-expressing
cells in the PFC and in several regions of the HIP
To determine whether the increased Agmat expression in Crtc1−/−
mice was because of higher Agmat levels or an increased number
of Agmat-expressing cells, we visualized Agmat protein expression
using immunoﬂuorescence in the PFC and in the CA1, CA3 and
dentate gyrus (DG) subregions of the HIP (Figure 2). Staining
revealed numerous cells in the PFC (Figure 2a), and in the DG
(Figure 2b), CA1 (Figure 2c) and CA3 (Figure 2d) regions of the HIP,
and its subcellular localization appeared mainly perinuclear within
those structures. In the HIP, staining could be observed in the
pyramidal cell layer, but appeared stronger in interneuron-like
cells. Agmat-expressing cells were counted and results were
normalized to total numbers of cells, counted with 4,6-diamidino-
2-phenylindole staining (Figure 2e). Agmat-positive cells counting
revealed a signiﬁcant increased number of cells in the PFC of
Crtc1−/− mice (+60%, t=− 4.23, df = 9, P= 0.001) as compared with
WT littermates. This could also be observed in the DG (+45%,
t=− 2.55, df = 9, P= 0.029) and CA1 regions of the HIP (+70%,
Male Female
Figure 1. Increased levels of agmatinase (Agmat) in Crtc1−/− mice. (a) Real-time quantitative PCR measurements showed an increased
expression of Agmat in the hippocampus (HIP) and prefrontal cortex (PFC) of male Crtc1−/− mice (n= 5) compared with wild-type (WT)
littermates (n= 5). (b) Agmat was also overexpressed in the HIP and PFC of female Crtc1−/−mice (n= 6) compared with WT control mice (n= 5).
Representative western blot of Agmat and β-actin is shown in c for male mice and in e for female mice. Quantitative analyses of western blot
showed increased protein levels of Agmat in the HIP of male Crtc1−/− mice (n= 4) compared with WT mice (n= 5; d). Protein levels of Agmat
were also increased in the HIP of female Crtc1−/− mice (n= 6) compared with WT mice (n= 5; f). Results are presented as ratio between Agmat
and β-actin signals. Data are mean± s.e.m. *Po0.5, ***Po0.001.
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Figure 2. Increased number of agmatinase (Agmat)-expressing cells in male Crtc1−/− mice. Representative immunoﬂuorescence staining of
Agmat-expressing cells (red) and total cells (4,6-diamidino-2-phenylindole (DAPI) staining) in the prefrontal cortex (PFC; a), and in the dentate
gyrus (DG; b), CA1 (c) and CA3 (d) regions of the hippocampus (HIP). Cell counting resulted in an increased number of Agmat-expressing cells
in the PFC, DG and CA1 regions of male Crtc1−/− mice (n= 6) compared with wild-type (WT) littermates (n= 5; e). No difference in number of
Agmat-expressing cells was found in the CA3 region. Results are expressed as ratio between number of Agmat-expressing cells and total
number of cells. Data are mean ± s.e.m. *Po0.5, **Po0.01. Scale bar, 50 μm.
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t=− 2.28, df = 9, P= 0.049). No differences in the numbers of
Agmat-expressing cells could be seen in the CA3 region of the HIP
(t=− 0.40, df = 9, P= 0.698). Overall, these data suggest that the
increased Agmat expression found in Crtc1−/− mice would be the
result of a higher number of Agmat-expressing cells in the PFC
and selected HIP subregions. Moreover, the morphology and
localization of the hippocampal cells expressing higher Agmat
levels indicated that they could be GABAergic interneurons.
Characterization of Agmat-expressing cells in the PFC and HIP
As hippocampal Agmat-expressing cells have an interneuron-like
morphology, we characterized Agmat-expressing cells with
markers for speciﬁc GABAergic interneuron types. Bernstein
et al.44 studied regional and cellular expression of Agmat in the
rat brain and found that Agmat colocalized with calretinin (CR)-
expressing interneurons in the cortex and CA1 region of the HIP.44
We therefore performed double immunolabeling of CR and Agmat
in the PFC and HIP of WT mice (Figure 3 and Supplementary
Figure S1). In the PFC, we observed very little colocalization
between CR and Agmat staining (Figure 3a, double-labeled cells
indicated with arrows). Little colocalization was also seen in the
CA3 region of the HIP (Figure S1b). Moreover, no colocalization
was observed in the DG and CA1 regions of the HIP (Figure 3b and
Supplementary Figure S1a, respectively). In order to further
investigate which type of interneurons expressed Agmat, we
performed double immunostaining of Agmat- and PV-expressing
cells. We observed high colocalization of Agmat and PV cells in all
studied structures: PFC, DG, CA1 and CA3 regions of the HIP
(Figures 3c and d and Supplementary Figure S1c and d,
respectively). Indeed, nearly all PV-expressing cells were also
Agmat-positive. On the other hand, there were some Agmat-
expressing cells that were not PV-positive, therefore suggesting
that other types of cells express Agmat.
Several lines of evidence involved somatostatin (Sst) in mood
disorders,45 and we previously observed that Sst was down-
regulated in the brain of Crtc1−/− mice.13 Therefore, we
investigated whether Agmat might be expressed in somatostati-
nergic interneurons by performing double immunostaining of
Agmat- and Sst-expressing cells. As for PV staining, most of Sst-
expressing cells were colocalized with Agmat in all regions
observed: PFC, DG, CA1 and CA3 regions of the HIP (Figures 3e
and f and Supplementary Figure S1e and f, respectively).
Colocalization was, however, less extended in the PFC; as some
Sst-expressing cells were not colocalized with Agmat staining.
Altogether, these data conﬁrm the expression of Agmat in
speciﬁc GABAergic interneuron subpopulations, with apparent
high expression in PV and Sst interneurons, and slight colocaliza-
tion with CR interneurons.
Rapid ketamine-like antidepressant effect of acute agmatine in
male and female WT and Crtc1−/− mice
Given the possible role of an agmatine deﬁcit in depression and
the observed increase in Agmat levels in the brain of Crtc1−/−
mice, we postulated that their depressive-like behavior is due, at
least in part, to a dysregulated agmatinergic system. To test this
hypothesis, we treated WT and Crtc1−/− mice with acute
intraperitoneal (IP) injections of agmatine and tested antidepres-
sant effects in the FST, a classical test for rodent depression-
related behavior. We hypothesized that restoring agmatine levels
by exogenous supplementation would normalize behavioral
response to the helplessness-inducing effects of FST. We ﬁrst
treated the animals with agmatine at 10 mg kg− 1 and compared
their depressive-like behavior in the FST with saline-injected
control animals. This protocol was repeated a second time on the
next day. The antidepressant effects of agmatine were assessed by
measuring the ﬂoating (immobility) time of the mice. Agmatine
had a signiﬁcant antidepressant effect on WT mice but failed to
signiﬁcantly reduce Crtc1−/− mouse immobility time (data not
shown). However, a tendency to decrease the immobility time of
Crtc1−/− mice prompted us to repeat this experiment with an
increased dose of agmatine (50 mg kg− 1, IP; Figures 4a and b). For
male mice (Figure 4a), a signiﬁcant effect of genotype on
immobility could be seen on both days of test, as shown by
two-way ANOVA (Day 1: F(1,29) = 6.74, P= 0.014; Day 2: F(1,29) = 19.4,
Po0.001). Post hoc analyses revealed that vehicle-treated Crtc1−/−
mice presented higher immobility time than WT mice (Day 1:
+13%, P= 0.031, Day 2: +22%, P= 0.004). A signiﬁcant treatment
effect could be observed on the second day of test (F(1,29) = 12.38,
P= 0.001) as agmatine signiﬁcantly decreased the immobility time
of WT and Crtc1−/− mice (P= 0.012 and P= 0.026, respectively). For
female mice (Figure 4b), the analysis of immobility time by two-
way ANOVA revealed a signiﬁcant treatment effects for both days
of test (Day 1: F(1,28) = 10.28, P= 0.003; Day 2: F(1,28) = 23.46,
Po0.001). Post hoc analyses showed that agmatine signiﬁcantly
reduced immobility time in WT female mice on day 1 (−30%,
P= 0.014) and of both genotypes on day 2 (WT: − 30%, P= 0.003;
Crtc1−/−: − 30%, P= 0.001). Thus, 50 mg kg− 1of agmatine reduced
the immobility time of male and female Crtc1−/− mice. Overall,
these data conﬁrm the antidepressant effect of an acute agmatine
treatment in WT animals. Crtc1−/− mice also respond to the
antidepressant effect of agmatine, but require a higher dose
(50 mg kg− 1).
Ketamine and other NMDAR antagonists have been shown to
have rapid and long-lasting antidepressant effects in behavioral
despair paradigms such as the FST.27 As agmatine also acts as a
NMDAR antagonist,24 we assessed the antidepressant effect
of ketamine in male and female WT and Crtc1−/− mice
(Supplementary Figure S2). Interestingly, ketamine (3 mg kg− 1,
IP) signiﬁcantly decreased the depressive-like behavior of WT and
Crtc1−/− mice of both sexes in a very similar way as agmatine did,
which suggested that the rapid antidepressant action of agmatine
and ketamine may involve the same molecular pathways.
Characterization of pathways involved in agmatine antidepressant
effect
Although agmatine antidepressant effects have been established,
the underlying molecular mechanisms remain unclear. A recent
study suggested that chronic agmatine treatment induces an
increase of BDNF protein levels, as well as an increased
phosphorylation of CREB, PKA and other kinases involved in
pathways associated with neuroplasticity.40 Although the under-
lying cellular and molecular mechanisms of ketamine’s antide-
pressant action are not completely understood, they involve the
rapid induction of BDNF translation via activation of the
mammalian target of rapamycin (mTOR) pathway as seen by
dephosphorylation of eEF2.27 Therefore, we investigated whether
agmatine’s rapid antidepressant effect involved NMDAR blockade-
associated changes in BDNF levels and eEF2 phosphorylation. We
measured the levels of phospho-eEF2 and BDNF proteins in the
PFC and HIP of male and female mice treated with 50 mg kg− 1
(Figures 4c-j). Western blot for phospho-eEF2 and total eEF2
showed a single band at the expected size of 95 kDa (Figures 4c
and d). Phospho-eEF2 signal was quantiﬁed and normalized over
total eEF2 signal. In male mice (Figure 4e), a two-way ANOVA
showed no effect of genotype or treatment in the HIP. A signi-
ﬁcant effect of genotype could be seen in the PFC (F(1,23) = 13.34,
P= 0.001) as both groups of Crtc1−/− mice presented lower
levels of phospho-eEF2 (P= 0.001 and P= 0.002). Agmatine
treatment had no effect on p-eEF2 levels of Crtc1−/− mice, but it
signiﬁcantly reduce p-eEF2 in WT mice (P= 0.04). In female mice
(Figure 4f), a two-way ANOVA showed no effect of genotype or
treatment in the HIP. A trend to decreased levels of phosphory-
lated eEF2 was present in agmatine-treated WT mice and in both
groups of Crtc1−/− animals. In the PFC, signiﬁcant effects of
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Figure 3. Characterization of GABAergic interneuron subpopulations expressing agmatinase (Agmat) in the prefrontal cortex (PFC) and
hippocampus (HIP) of wild-type (WT) male mice. Double immunoﬂuorescence labeling of (a, b) Agmat and calretinin (CR; c, d) Agmat and
parvalbumin (PV), and (e, f) Agmat and somatostatin (Sst) in (a, c, e) PFC and (b, d, f) dentate gyrus (DG) of the HIP. Total cells were identiﬁed
by nuclear 4,6-diamidino-2-phenylindole (DAPI) staining. Merged images showed few colocalization of Agmat and CR staining in the PFC (a)
as indicated by arrows. No colocalization could be observed in the DG (b). All PV and Sst interneurons also expressed Agmat in the PFC (c, e)
and DG (d, f). Scale bar, 50 μm.
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genotype (F(1,13), P= 0.011), treatment (F(1,13), P= 0.043) and
genotype× treatment (F(1,13), P= 0.011) were observed. Post hoc
analyses revealed that agmatine signiﬁcantly decreased the
phosphorylation of eEF2 in WT mice (P= 0.003). Both groups of
Crtc1−/− mice also presented decreased levels of phospho-eEF2 as
compared with vehicle-treated WT mice (Crtc1−/− Vehicle:
P= 0.001; Crtc1−/− Agmatine: P= 0.002). Agmatine had no effect
on the phosphorylation of eEF2 in Crtc1−/− mice.
Western blot for BDNF revealed a single band at the expected
size of 14 kDa (Figures 4g–h). BDNF signal was quantiﬁed and
normalized with β-actin signal. In male mice (Figure 4i), no effect
of genotype or treatment could be observed in the HIP. In the PFC,
a two-way ANOVA showed an effect of genotype (F(1, 23) = 29.12,
Po0.001). Post hoc analysis revealed that both vehicle- and
agmatine-treated Crtc1−/− mice presented lower levels of BDNF
protein than WT mice (Po0.001 for both groups). Agmatine
Rapid antidepressant effect of agmatine in Crtc1 null mice
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treatment had no effect on BDNF levels of WT and Crtc1−/− mice.
In female mice (Figure 4j), a two-way ANOVA revealed a signiﬁcant
effect of genotype in both structures (PFC: F(1,22) = 6.78, P= 0.016;
HIP: F(1,22) = 6.27, P= 0.02). Post hoc analyses showed that both
groups of Crtc1−/− mice had signiﬁcantly lower levels of BDNF
than WT animals in the HIP, independently of the treatment
(P= 0.01). No effect of agmatine treatment could be seen in the
HIP, whereas it was signiﬁcant in the PFC (F(1,22) = 4.63, P= 0.042).
Post hoc analyses indicated that agmatine signiﬁcantly increased
BDNF protein levels in the PFC, however, only in WT mice
(P= 0.024). Taken together, these results provide evidence that
agmatine induces eEF2 dephosphorylation in WT male and female
mice, thus suggesting activation of the mTOR pathway, through
its NMDAR antagonist property. Agmatine effects on BDNF levels
are gender-dependent, as agmatine rapidly induces BDNF
translation in WT female mice, but not in WT male mice.
DISCUSSION
In this study, we showed for we believe the ﬁrst time a link
between downregulation of the CRTC1–CREB pathway and
alteration of the agmatinergic system in the context of a rodent
model of depression. We found that CRTC1-deﬁcient mice exhibit
increased mRNA and protein levels of Agmat in the HIP and PFC.
We also determined that these higher Agmat levels are mainly
because of an increased number of Agmat-expressing cells in the
PFC and HIP of Crtc1−/− mice. These ﬁndings suggest that Crtc1−/−
mice have a dysregulated agmatinergic system resulting in
increased Agmat expression and ensuing decreased agmatine
levels. Hence, the depressive-like phenotype of these animals
would be in keeping with the protective and antidepressant role
of endogenous agmatine.
Immunoﬂuorescent detection of Agmat revealed that this
enzyme is mainly expressed in interneurons in accordance with
a previous characterization in the rat brain.44 As Crtc1−/− mice
have more Agmat-expressing cells, these mice might also have
overall GABAergic system alteration. In line with this, agmatine
and GABA seem to be closely related because agmatine is
degraded into putrescine, whose derived polyamines can be used
as GABA precursors.16 Therefore, we hypothesize that dysregula-
tion of agmatine metabolism might lead to abnormal GABA
regulation and ultimately to overall impaired interneuronal
circuitry.
A characterization of the subpopulations of GABAergic inter-
neurons expressing Agmat showed that it mainly colocalizes with
PV and Sst interneurons, whereas no or little colocalization with CR
interneurons was observed. These ﬁndings are in contradiction
with the study of Bernstein et al.,44 which showed that Agmat was
mainly found in CR interneurons. The reason for this discrepancy is
unclear. Future studies should focus on a deeper characterization
of Agmat-expressing cells, as Agmat staining revealed that it is
present in many cells in the mouse brain and thus probably in a
wide range of cell types.
The depressive-like behavior of Crtc1−/− mice was successfully
normalized by acute agmatine treatment as efﬁciently as
ketamine’s effect. This suggests that their altered agmatinergic
system contributes to their phenotype. It is noteworthy that only a
higher dose of agmatine (50 mg kg− 1) was effective, suggesting
that the 10 mg kg− 1 dose was not sufﬁcient to compensate for a
possible decrease in agmatine levels and to restore normal
agmatinergic functions.
When looking at the molecular effects of agmatine, we found
that it was able to induce an increase in BDNF protein levels in the
PFC of WT females. This agmatine-induced BDNF upregulation was
paralleled by eEF2 dephosphorylation, which stimulates protein
translation. This mechanism has been shown to underlie the rapid
antidepressant effect of NMDAR antagonists such as ketamine and
MK-801.26,27,46 Therefore, our results suggest that agmatine acts as
an antidepressant, possibly through this pathway. This is in line
with the ability of agmatine to block NMDAR and the involvement
of this function in its antidepressant effects.36,47,48 In contrast, the
behavioral effects of agmatine in WT males were apparently not
mediated by BDNF because agmatine did not increase its levels in
HIP and PFC. The mechanisms that underlie these sex differences
are still unclear, but not completely unexpected. These gender-
speciﬁc effects are actually of much interest in the light of the
female preponderance in major depression. Sex differences have
been reported in animal models of depression. For instance, the
impact of BDNF signaling on depression-like behavior is different
in male and female mice.49 Moreover, it has been shown that
hippocampal NO may contribute to sex difference in depressive-
like behaviors.50 This study showed that stress promotes
hippocampal NO production in male mice, whereas stress
suppresses it in female ones. Worthy of note, both NO excess in
male mice and shortage in female mice resulted in depressive-like
behaviors through affecting CREB activation.
Figure 4. Behavioral and molecular effects of agmatine treatment on male and female wild-type (WT) and Crtc1−/− mice. (a, b) Effects of acute
agmatine treatment (50 mg kg− 1, intraperitoneal (IP)) 30 min before a forced swim test (FST) during two consecutive days. In male mice
(a) vehicle-treated Crtc1−/− mice (n= 7) showed higher immobility levels than vehicle-treated WT mice (n= 9) on both days of test (+Po0.05,
++Po0.01). On Day 2, agmatine signiﬁcantly decreased the immobility time of WT mice (*Po0.05) and Crtc1−/− mice (#Po0.05; n= 10 and
n= 7, respectively). In female mice (b) WT mice treated with agmatine (n= 8) showed signiﬁcantly decreased immobility time (*Po0.05,
**Po0.01) compared with vehicle-treated WT mice (n= 9) on both days of test. On day 2, agmatine-treated Crtc1−/− mice (n= 8) also
presented signiﬁcantly decreased immobility time (##Po0.01) than vehicle-treated Crtc1−/− mice (n= 8). (c–f) Effects of acute agmatine
treatment (50 mg kg− 1, IP) on eukaryotic elongation factor 2 (eEF2) phosphorylation. (c, d) A representative western blot for phospho-eEF2
and total eEF2 in the hippocampus (HIP) and prefrontal cortex (PFC) of WT and Crtc1−/− mice (V, vehicle-treated; A, agmatine-treated) in male
(c) and female (d) mice. (e, f) Quantitative analyses of p-eEF2 western blot in male (e) and female (f) mice. In male mice, no effect of agmatine
could be seen in the HIP of WT and Crtc1−/− mice. In the PFC, agmatine-treated WT mice (n= 8) presented lower levels of p-eEF2 than vehicle-
treated WT mice (n= 7; *Po0.05). Both vehicle- and agmatine-treated Crtc1−/− mice (n= 6 for both) displayed lower p-eEF2 levels than WT
mice (++Po0.01); agmatine treatment had no effect on p-eEF2 levels in these animals (e). In female mice, quantiﬁcation showed no effect of
agmatine treatment in the HIP of WT and Crtc1−/− mice (f). In the PFC, agmatine-treated WT mice (n= 4) presented lower levels of eEF2
phosphorylation compared with vehicle-treated WT animals (n= 4; **Po0.01). Crtc1−/− mice treated with vehicle (n= 5) or agmatine (n= 5)
also displayed lower levels of eEF2 phosphorylation than WTmice (**Po0.01). Agmatine treatment had no effect on Crtc1−/−mice. Results are
presented as ratio between phospho-eEF2 and total eEF2 signals. (g–j) Effects of acute agmatine treatment (50 mg kg− 1, IP) on brain-derived
neurotrophic factor (BDNF) protein level. (g, h) A representative western blot for BDNF and β-actin in the HIP and PFC of WT and Crtc1−/−mice
in male (g) and female (h) mice. (i, j) Quantitative analyses of BDNF western blot in male (i) and female (j) mice. In male mice, no effect of
agmatine could be seen in the HIP of WT and Crtc1−/− mice. In the PFC, both vehicle- and agmatine-treated Crtc1−/− mice (n= 6 for both)
displayed lower BDNF levels than vehicle- and agmatine-treated WT mice (n= 7 and n= 8, respectively; +++Po0.001) (i). In female mice,
quantitative analyses of western blot showed decreased levels of BDNF in the HIP of all Crtc1−/− animals (n= 14) compared with WT animals
(n= 13), independently of the treatment (+Po0.05). In the PFC, agmatine-treated WT mice (n= 7) presented higher levels of BDNF compared
with vehicle-treated WT animals (n= 5; *Po0.05). Crtc1−/−mice treated with agmatine (n= 8) did not present different BDNF levels than those
treated with saline (n= 6; j). Results are presented as ratio between BDNF and β-actin signals. Data are mean± s.e.m.
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Interestingly, the effects of agmatine on BDNF and eEF2 were
restricted to WT animals. Crtc1−/− male and female mice displayed
basal lower levels of phospho-eEF2 in the PFC, and agmatine did
not decrease them further nor did it increase BDNF levels, which
suggest a dysregulation of this pathway and the involvement of
alternative mechanisms underlying agmatine’s antidepressant
effects in these animals.
In conclusion, our results provide evidence for the involvement of
the agmatinergic system in the Crtc1−/−mouse model of depression,
and lend support to previous reports of the antidepressant
properties of agmatine. The comparable rapid antidepressant effects
of agmatine and ketamine in WT and Crtc1−/− mice, as well as the
molecular effects that acute agmatine treatment causes in the brain
of WT mice suggest that agmatine possibly functions as a fast-acting
antidepressant through NMDAR blockade. The relationship between
the CRTC1–CREB pathway and agmatine regulation merits further
investigation, as it will bring better knowledge of these systems and
their contribution to MDD etiology.
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